EGYPTIAN STREETS: 研究者推特称埃及COVID-19患者达19310,比官方数字高百倍,受到73名科学家联名谴责

2020-03-23 医咖会 医咖会

上周,来自世界各地的73名埃及裔科学家给多伦多大学校长写了一封信,谴责多伦多综合医院研究所(TGHRI)临床研究员Isaac Bogoch博士故意“向公众发布不准确的估计数据”

上周,来自世界各地的73名埃及裔科学家给多伦多大学校长写了一封信,谴责多伦多综合医院研究所(TGHRI)临床研究员Isaac Bogoch博士故意“向公众发布不准确的估计数据”。信中表示,Isaac Bogoch博士3月15日在推特上发布了虚假信息,称“估计埃及的COVID-19病例数为19310”。而据WHO官方通报,截止2020年3月16日,埃及的确诊病例数为126例。

Isaac Bogoch博士发布的推特

这些埃及科学家要求大学对Bogoch博士的科学不端行为展开调查,表示Bogoch博士在发布这些数据时违反了科学规范。

专家组们同时批评了《卫报》发表了Bogoch博士的相关报道,也批评了《纽约时报》记者Declan Walsh在推文中发布了该数字,不过该推文已被删除。

Declan Walsh的推文


以下是该信件的内容:

随着Covid-19大流行迅速升级,各国正在采取史无前例的措施来限制疾病的传播。不负责任地传播错误信息,会引起公众恐慌,可能对国家造成重大甚至灾难性的经济影响。

我们是来自全球的埃及裔科学家和研究人员,对多伦多大学的一名流行病学家所提供的不负责任的信息感到愤怒,该信息最近在埃及引起了严重的恐慌,并可能造成严重的经济后果。多伦多综合医院研究所(TGHRI)的临床研究人员Isaac Bogoch博士在3月15日发布的推文中表示,其研究团队估计埃及的Covid-19病例数为19310(95%CI:6270-45070),而这比WHO报告中的数字高出很多。截止2020年3月16日,WHO官方网站报告埃及有126例病例,2例死亡和27例康复。

Bogoch博士声称,他的这一研究向一个医学期刊提交了简短手稿,但未发表。他也向WHO提交了数据,并计划发布完整的预印本,但是被预印本网站拒绝了。当有人对其估算数据提出质疑时,他回应说最初的数字确实高估了,后来又将数字改为了6000。

我们希望多伦多大学对Bogoch博士展开调查,原因如下:

1. Bogoch博士向预印本网站上提交的手稿遭到拒绝后,他仍坚持将这个不准确的数据向公众发布。

2. 《卫报》于2020年3月15日当天发表了题为“Egypt rate of Coronavirus cases likely to be higher than figures suggest(埃及的新冠病例数可能比目前看到的更高)”的新闻,指出多伦多大学一名传染病学家提供了更为严峻的传播情况。如您所见,这篇文章在埃及引起了极大的恐慌。

3. Declan Walsh是这篇《卫报》文章的作者以及《纽约时报》驻埃及记者,在推特上引用了Bogoch博士的发现,并发布了这一数字(19000),同样引起了恐慌。他后来删除了自己的推文,并指出目前的估计值更低,为6000。

4. 即使论文被接收,新闻报纸也应该遵守规则,只有当期刊发布该论文后,才能发布新闻报道。Bogoch博士在推特上发布的这些数据,违反了科学规范性,虽然他和报纸撤回了这些推送,但已经对埃及社会造成了重大破坏。

出于对多伦多大学及科学家们的敬意,我们希望大学对Bogoch博士的科学不当行为进行调查,并采取必要的行动。我们保留对Bogoch博士、《卫报》和多伦多大学提起诉讼的权利。

原始出处:
73 Egyptian Scientists Decry ‘Inaccurate’ Estimate of COVID-19 Cases in Egypt. EGYPTIAN STREETS. MARCH 17, 2020

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1785145, encodeId=af911e85145c1, content=<a href='/topic/show?id=4ac566127e' target=_blank style='color:#2F92EE;'>#Egyptian#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6612, encryptionId=4ac566127e, topicName=Egyptian)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b71f2500114, createdName=1179102698_36768926, createdTime=Sun Dec 06 11:19:08 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785144, encodeId=4b941e85144ae, content=<a href='/topic/show?id=39c4661111' target=_blank style='color:#2F92EE;'>#Egypt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6611, encryptionId=39c4661111, topicName=Egypt)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Mon Jun 22 10:19:08 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032773, encodeId=e1252032e733d, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Wed Sep 09 05:19:08 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642228, encodeId=fe2c164222871, content=<a href='/topic/show?id=455e4156e69' target=_blank style='color:#2F92EE;'>#埃及#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41567, encryptionId=455e4156e69, topicName=埃及)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10c22881502, createdName=12498d2fm58(暂无昵称), createdTime=Mon Nov 16 23:19:08 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297416, encodeId=3451129e41616, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Wed Mar 25 10:19:08 CST 2020, time=2020-03-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1785145, encodeId=af911e85145c1, content=<a href='/topic/show?id=4ac566127e' target=_blank style='color:#2F92EE;'>#Egyptian#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6612, encryptionId=4ac566127e, topicName=Egyptian)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b71f2500114, createdName=1179102698_36768926, createdTime=Sun Dec 06 11:19:08 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785144, encodeId=4b941e85144ae, content=<a href='/topic/show?id=39c4661111' target=_blank style='color:#2F92EE;'>#Egypt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6611, encryptionId=39c4661111, topicName=Egypt)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Mon Jun 22 10:19:08 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032773, encodeId=e1252032e733d, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Wed Sep 09 05:19:08 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642228, encodeId=fe2c164222871, content=<a href='/topic/show?id=455e4156e69' target=_blank style='color:#2F92EE;'>#埃及#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41567, encryptionId=455e4156e69, topicName=埃及)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10c22881502, createdName=12498d2fm58(暂无昵称), createdTime=Mon Nov 16 23:19:08 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297416, encodeId=3451129e41616, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Wed Mar 25 10:19:08 CST 2020, time=2020-03-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1785145, encodeId=af911e85145c1, content=<a href='/topic/show?id=4ac566127e' target=_blank style='color:#2F92EE;'>#Egyptian#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6612, encryptionId=4ac566127e, topicName=Egyptian)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b71f2500114, createdName=1179102698_36768926, createdTime=Sun Dec 06 11:19:08 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785144, encodeId=4b941e85144ae, content=<a href='/topic/show?id=39c4661111' target=_blank style='color:#2F92EE;'>#Egypt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6611, encryptionId=39c4661111, topicName=Egypt)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Mon Jun 22 10:19:08 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032773, encodeId=e1252032e733d, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Wed Sep 09 05:19:08 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642228, encodeId=fe2c164222871, content=<a href='/topic/show?id=455e4156e69' target=_blank style='color:#2F92EE;'>#埃及#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41567, encryptionId=455e4156e69, topicName=埃及)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10c22881502, createdName=12498d2fm58(暂无昵称), createdTime=Mon Nov 16 23:19:08 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297416, encodeId=3451129e41616, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Wed Mar 25 10:19:08 CST 2020, time=2020-03-25, status=1, ipAttribution=)]
    2020-09-09 stfoxst
  4. [GetPortalCommentsPageByObjectIdResponse(id=1785145, encodeId=af911e85145c1, content=<a href='/topic/show?id=4ac566127e' target=_blank style='color:#2F92EE;'>#Egyptian#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6612, encryptionId=4ac566127e, topicName=Egyptian)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b71f2500114, createdName=1179102698_36768926, createdTime=Sun Dec 06 11:19:08 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785144, encodeId=4b941e85144ae, content=<a href='/topic/show?id=39c4661111' target=_blank style='color:#2F92EE;'>#Egypt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6611, encryptionId=39c4661111, topicName=Egypt)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Mon Jun 22 10:19:08 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032773, encodeId=e1252032e733d, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Wed Sep 09 05:19:08 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642228, encodeId=fe2c164222871, content=<a href='/topic/show?id=455e4156e69' target=_blank style='color:#2F92EE;'>#埃及#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41567, encryptionId=455e4156e69, topicName=埃及)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10c22881502, createdName=12498d2fm58(暂无昵称), createdTime=Mon Nov 16 23:19:08 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297416, encodeId=3451129e41616, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Wed Mar 25 10:19:08 CST 2020, time=2020-03-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1785145, encodeId=af911e85145c1, content=<a href='/topic/show?id=4ac566127e' target=_blank style='color:#2F92EE;'>#Egyptian#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6612, encryptionId=4ac566127e, topicName=Egyptian)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b71f2500114, createdName=1179102698_36768926, createdTime=Sun Dec 06 11:19:08 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785144, encodeId=4b941e85144ae, content=<a href='/topic/show?id=39c4661111' target=_blank style='color:#2F92EE;'>#Egypt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6611, encryptionId=39c4661111, topicName=Egypt)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Mon Jun 22 10:19:08 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032773, encodeId=e1252032e733d, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Wed Sep 09 05:19:08 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642228, encodeId=fe2c164222871, content=<a href='/topic/show?id=455e4156e69' target=_blank style='color:#2F92EE;'>#埃及#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41567, encryptionId=455e4156e69, topicName=埃及)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10c22881502, createdName=12498d2fm58(暂无昵称), createdTime=Mon Nov 16 23:19:08 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297416, encodeId=3451129e41616, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Wed Mar 25 10:19:08 CST 2020, time=2020-03-25, status=1, ipAttribution=)]

相关资讯

Preprint:COVID-19在人类宿主中会进化!

导言:目前,我们都面临着前所未有的流行病的威胁:COVID-19。它和其他冠状病毒有什么不同?它会减弱还是变得更具毒性?哪些动物可能是它最初的宿主?自第一次发现以来,它有没有发生过什么变化?这些问题对

英国COVID-19候选疫苗ChAdOx1:将于下个月开始临床试验

英国公共卫生(PHE)部门研究人员正在对COVID-19候选疫苗ChAdOx进行临床前测试。

FDA不建议COVID-19患者使用非甾体抗炎药(NSAID)

FDA报道指出,使用非甾体抗炎药(NSAID)(如布洛芬)可能会使新型冠状病毒(COVID-19)肺炎恶化。

Stabilitech公司开发出COVID-19疫苗的口服胶囊,患者可自行服用

Stabilitech Biopharma 公司宣布已经开发出新型的用于递送COVID-19疫苗的口服胶囊,该新型冠状病毒疫苗安全、有效并且可以让患者自行服用。

IVIG联合低分子肝素抗凝治疗对COVID-19重症比较有效

2020年3月20日,一篇以李太生教授和曹玮副教授为通讯作者的文章于

nature: 估算中国武汉的COVID-19总体病死风险

《自然-医学》发表的一篇论文Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, Chin